DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.

Compound Y-1 is a novel neuraminidase inhibitor.

Negletein has anti-inflammatory and immunomodulatory activities via inhibition of TNF-α, iNOS and IL-1β.